跳至主要内容
临床试验/NCT02455050
NCT02455050已完成3 期

A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief

Allergan0 个研究点目标入组 79 人开始时间: 2014年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Allergan
入组人数
79
主要终点
Tolerability Survey Score Using a 100 Unit Visual Analog Scale (VAS) in Period 1

研究概览

简要总结

A study to evaluate the tolerability and acceptability of an investigational eye drop formulation in patients with Dry Eye Disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Current use of an artificial tear product
  • Visual Acuity of at least 20/40 (while wearing glasses, if necessary).

排除标准

  • Use of contact lenses in the last 3 months, or anticipated use of contact lenses during the study
  • Cataract surgery, laser-assisted in situ keratomileusis (LASIK), photorefractive keratectomy within 6 months
  • Use of RESTASIS® Cyclosporine Ophthalmic Emulsion or any topical cyclosporine within 3 months
  • Diagnosis of glaucoma.

研究组 & 干预措施

New Eye Drop Formulation then Systane®

Other

1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks.

干预措施: Carboxymethylcellulose Sodium Based Eye Drops (Drug)

New Eye Drop Formulation then Systane®

Other

1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks.

干预措施: Systane® Gel Drops (Drug)

Systane® then New Eye Drop Formulation

Other

1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.

干预措施: Carboxymethylcellulose Sodium Based Eye Drops (Drug)

Systane® then New Eye Drop Formulation

Other

1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.

干预措施: Systane® Gel Drops (Drug)

Genteal® then New Eye Drop Formulation

Other

1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.

干预措施: Carboxymethylcellulose Sodium Based Eye Drops (Drug)

Genteal® then New Eye Drop Formulation

Other

1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.

干预措施: Genteal® Lubricant Gel Drops (Drug)

New Eye Drop Formulation then Genteal®

Other

1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks.

干预措施: Carboxymethylcellulose Sodium Based Eye Drops (Drug)

New Eye Drop Formulation then Genteal®

Other

1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks.

干预措施: Genteal® Lubricant Gel Drops (Drug)

结局指标

主要结局

Tolerability Survey Score Using a 100 Unit Visual Analog Scale (VAS) in Period 1

时间窗: After 14 days of treatment in Period 1 (Follow-up 1 Day 14)

Tolerability was assessed using an 8-item survey consisting of 4 positive questions: comfort, soothing, moistening/lubricating and vision clarity and 4 negative questions: stickiness, blur, burning/stinging and discomfort. Participants were instructed to think about their experience over the past week and place a vertical line on the line that best captured how they felt the first 30 minutes after the study drops were administered using the scale: 0 far left of the line to 100 far right on the line. The individual positive scores are added together to obtain the total positive tolerability score from 0 (worst) to 400 (best) and the individual negative scores are added together to obtain the total negative tolerability score for a total possible score of 0 (best) to 400 (worst).

Tolerability Survey Score Using a 100 Unit Visual Analog Scale (VAS) in Period 2

时间窗: After 14 days of treatment in Period 2 (Follow-up 2 Day 35)

Tolerability was assessed using an 8-item survey consisting of 4 positive questions: comfort, soothing, moistening/lubricating and vision clarity and 4 negative questions: stickiness, blur, burning/stinging and discomfort. Participants were instructed to think about their experience over the past week and place a vertical line on the line that best captured how they felt the first 30 minutes after the study drops were administered using the scale: 0 far left of the line to 100 far right on the line. The individual positive scores are added together to obtain the total positive tolerability score from 0 (worst) to 400 (best) and the individual negative scores are added together to obtain the total negative tolerability score for a total possible score of 0 (best) to 400 (worst).

次要结局

  • Tear Break-Up Time With Fluorescein in Period 1(After 14 days of treatment in Period 1 (Follow-up 1 Day 14), 5 and 30 minutes post drop instillation)
  • Percentage of Participants Selecting Strongly Agree or Agree in the Acceptability Survey Score Using a 5-Point Scale in Period 1(After 14 days of treatment in Period 1 (Follow-up 1 Day 14))
  • Distance Visual Acuity in Period 1(After 14 days of treatment in Period 1 (Follow-up 1 Day 14), 5 and 30 minutes post drop instillation)
  • Ocular Surface Disease Index© (OSDI©) Score Using a 5-Point Scale in Period 1(Baseline and after 14 days of treatment in Period 1 (Follow-up 1 Day 14))
  • Percentage of Participants Selecting Strongly Agree or Agree in the Acceptability Survey Score Using a 5-Point Scale in Period 2(After 14 days of treatment in Period 2 (Follow-up 2 Day 35))
  • Percentage of Participants by Response in End of Study Survey: Assessing Comfort, Blur, and Relief of Symptoms (New Eye Drop Formulation Versus Systane®)(Day 35)
  • Ocular Surface Disease Index© (OSDI©) Score Using a 5-Point Scale in Period 2(Baseline and after 14 days of treatment in Period 2 (Follow-up 2 Day 35))
  • Subjective Evaluation of Symptoms of Dryness (SESoD) Score Using a 5-Point Scale in Period 1(Baseline and After 14 days of treatment in Period 1 (Follow-up 1 Day 14))
  • Percentage of Participants by Response in End of Study Survey: Assessing Comfort, Blur, and Relief of Symptoms (New Eye Drop Formulation Versus Genteal®)(Day 35)
  • Subjective Evaluation of Symptoms of Dryness (SESoD) Score Using a 5-Point Scale in Period 2(Baseline and After 14 days of treatment in Period 2 (Follow-up 2 Day 35))
  • Distance Visual Acuity in Period 2(After 14 days of treatment in Period 2 (Follow-up 2 Day 35), 5 and 30 minutes post drop instillation)
  • Tear Break-Up Time With Fluorescein in Period 2(After 14 days of treatment in Period 2 (Follow-up 2 Day 35), 5 and 30 minutes post drop instillation)
  • Eye Drop Experience Survey Score: Assessing Vision, Comfort, and Relief of Symptoms in Period 1(After 14 days of treatment in Period 1 (Follow-up 1 Day 14), 5 and 30 minutes post drop instillation)
  • Eye Drop Experience Survey Score: Assessing Vision, Comfort, and Relief of Symptoms in Period 2(After 14 days of treatment in Period 2 (Follow-up 2 Day 35), 5 and 30 minutes post drop instillation)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验